Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

THE OFFERING
 
Common stock offered            shares
 
Common stock to be outstanding after this offering            shares
 
Use of proceeds We expect to use the net proceeds from this offering to fund clinical development of our product candidates and for working capital and other general corporate purposes. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products.
 
Proposed Nasdaq Global Market symbol OREX
 
The number of shares of common stock to be outstanding after this offering is based on 37,720,558 shares outstanding as of December 31, 2006, after giving effect to the conversion of all of our shares of preferred stock outstanding as of December 31, 2006 into shares of common stock, and excludes:
 
  •      4,594,125 shares of common stock issuable upon the exercise of options outstanding as of December 31, 2006 at a weighted average exercise price of $0.62 per share; and
 
  •                 shares of our common stock reserved for future issuance under our 2007 equity incentive award plan, which will become effective on the day prior to the day on which we become subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act (including 1,516,479 shares of common stock reserved for future grant or issuance under our 2004 stock plan, which shares will be added to the shares to be reserved under our 2007 equity incentive award plan upon the effectiveness of the 2007 equity incentive award plan).
 
Except as otherwise indicated, all information in this prospectus assumes:
 
  •      no exercise by the underwriters of their option to purchase up to an additional           shares of common stock to cover overallotments;
 
  •      the filing of our amended and restated certificate of incorporation and amended and restated bylaws upon completion of this offering;
 
  •      the conversion of all outstanding shares of our preferred stock into 32,924,474 shares of common stock upon completion of this offering; and
 
  •      a one-for-    reverse stock split of our common stock to be effected before the completion of this offering.


6